Abstract Clinical onset of type 1 diabetes (T1D) is thought to result from a combination of overt beta cell loss and beta cell dysfunction. However, our understanding of how beta cell metabolic abnormalities arise during the pathogenesis of disease remains incomplete. Despite extensive research on the autoimmune nature of T1D, questions remain regarding the time frame and nature of beta cell destruction and dysfunction. This review focuses on the characterizations of beta cell dysfunction in the prediabetic and T1D human and mouse model. Studies have shown evidence supporting progressive loss of beta cell mass and function prior to T1D onset, while other scientists argue beta cell destruction occurs later in the disease process. Determining the time frame of beta cell destruction and identifying metabolic mechanisms that drive beta cell dysfunction has high potential for successful interventions to maintain insulin secretion for individuals with established T1D as well as those with prediabetes.
Introduction
Hyperglycemia and insulinopenia are hallmark clinical phenotypes associated with type 1 diabetes (T1D). A reduction in the capacity to secrete insulin in response to macronutrients precedes the onset of T1D in most cases. As T1D is classically considered an autoimmune disease, the loss of function has been declared to occur as a result of beta cell loss. Histologic evidence supports such a notion as both islet number and insulin positive area are reduced or absent in almost all postmortem samples taken from individuals diagnosed with T1D, even those with a recent onset. Prior to diagnosis the loss of beta cells may be occurring, but silently. Accordingly, loss of function can only be detected using longitudinal metabolic tests, such as mixed-meal or glucose tolerance tests. Residual beta cell function persists in most patients subsequent to diagnosis, however, erosion of insulin release continues until it falls below detectable levels in most patients. Not only is the loss of mass and function "silent", but also data at this time have yet to emerge that link loss of function with loss of mass.
In the past 4 decades, we have made enormous progress in diagnostic techniques and treatment strategies based on our knowledge of genetic susceptibility and the use of autoantibodies as immunologic biomarkers [1] [2] [3] . Yet despite our increased understanding of the autoimmune nature of T1D, multiple questions remain regarding the exact nature and extent of beta cell destruction and dysfunction in T1D. While it is widely accepted that loss of insulin secretion occurs at least in part, because of beta cell death, we have a limited understanding of the metabolic abnormalities prior to beta cell destruction and during the progression of islet autoimmunity toward overt T1D. Little is known about the magnitude and significance of residual insulin production and beta cell function [4, 5] . Moreover, there is still controversy over the time frame of beta cell loss during the disease progression toward clinical diagnosis. Identifying metabolic mechanisms and predictors that drive beta cell dysfunction has high potential to influence the administration of interventions to maintain insulin secretion for individuals with established T1D as well as those with prediabetes. Here we discuss the current state of the art as well as identify major unknowns/challenges that must be met to better understand metabolic changes that occur prior to diagnosis of T1D.
T1D in Humans
Characterization of Beta Cell Function Before T1D Diagnosis Autoantibodies against beta cell autoantigens are indicators that mark the loss of self-tolerance and can indicate an early stage in the progression, or potential to progress to T1D. Metabolic measures, such as changes in circulating C-peptide [6] or the degree of change in first phase insulin release (FPIR) [7, 8] , allow for additional levels of risk for T1D to be assessed. Studies on the natural history of T1D have demonstrated that a progressive loss of FPIR in autoantibody positive (AAb + ) individuals represents a late stage in the period prior to diagnosis [9] [10] [11] [12] [13] [14] [15] [16] [17] . Further, a preservation of FPIR has been linked to failure to progress to T1D [6] . Early cross-sectional studies by Lo et al [18] have shown the occurrence of a temporal association between the presence of islet cell antibodies and a progressive decline in first phase inulin response (FPIR) to intravenous glucose tests (IVGTT) in what is known as the "prediabetic phase." A majority of studies have reported that the loss of FPIR is most pronounced in response to glucose in early "prediabetes" in comparison to other stimuli [12-14••] , pointing to a phase of β cell dysfunction well before diagnosis.
Results published to date have demonstrated that a differential sensitivity to secretagogues exists with those progressing to T1D becoming "blind" to glucose before responses to other secretagogues are lost [13, 14••] . Survival analysis by Barker et al [19] found that higher quartiles of 2-hour glucose and lower quartiles of FPIR at baseline were associated with decreased diabetes-free survival. Abnormal IVGTTs and/or abnormal oral glucose tolerance tests (OGTT) before the development of diabetes suggests altered glucose to insulin doseresponse relationship and loss of maximum insulin secretory response to glucose before disease onset. On the other hand, acute insulin response to arginine appears to be less altered with time, and increased basal glycemia remained substantial even at the onset of the disease [20] . This reinforces the supposition that even the prediabetic state may be associated with a glucose-specific beta cell functional abnormality in addition to a decreasing beta cell mass.
Loss of FPIR in response to glucose but not other secretagogues (arginine, tolbutamide, glucagon) would result from processes restricted to glucose, such as glucose transport and metabolism, but not shared mechanisms (ie, insulin production, ATP generation, or potassium channel activity). Studies using isolated islets from T1D patients have been limited but the published work supports the validity of this idea [21••, 22] . Immediately after isolation, islets from T1D patients lacked glucose stimulated insulin secretion (GSIS). The loss of GSIS was not linked to lower levels of insulin gene expression, but instead with a reduction in the level of mRNA for glucokinase and other members of the glycolysis pathway when compared with islets isolated from individuals without T1D [21••] . Interestingly, the islets isolated from patients with T1D also had heightened inflammation compared with controls [21••] . However, GSIS was recovered and inflammatory signals lost over the course of a 3-week culture [21••, 22] . The data from long-term islet culture suggest that the change in environment, from in vivo to in vitro, can induce β cell recovery. However, these data were generated from the islets of individuals diagnosed with T1D and it will take a similar effort studying islets from organ donors that are positive for T1D-relevant autoantibodies to begin to address the mechanism of beta cell dysfunction prior to onset of disease. Nonetheless, the correlation has provided clues to further investigate how inflammation leads to loss of GCK in insulin positive islets from individuals with established T1D.
Residual Beta Cell Mass
The commonly held view is that T1D develops because of the establishment of a nontolerogenic immune system and that beta cells fail as the result of autoimmune-mediated destruction. Spurred by findings in the non-obese diabetic (NOD) and biobreeding diabetes-prone (BB-DP) murine models, the perception is that the destruction continues until the insulin producing cells have been eliminated [23] and basal as well as stimulated c-peptide levels are undetectable. Recent publications have refuted this notion, by demonstrating that a significant number of patients with long-standing type 1 diabetes maintain both basal and stimulated c-peptide [4, 24••, 25, 26, 27 •], albeit reduced compared with the levels routinely measured in healthy controls. Quite striking was the prevalence of this phenotype in individuals with T1D, with these 3 studies reporting persistent c-peptide in 38 % [25] , 85 % [26] , and 67 % [24••] of the patients enrolled. A fourth and even more recent study using an insulin assay with very high sensitivity reported that MMTT-stimulated serum C-peptide was detectable at very low levels (>3.3 pmol/l) in 54 of 74 (73 %) individuals with long-standing T1D [28] . The increase in stimulated c-peptide challenges the belief that complete beta cell destruction is an inevitable consequence of disease progression, and indicates the presence of at least a small population of surviving beta cells. The presence of such a beta cell mass in patients with long-standing diabetes is intriguing as the potential exists for these cells to be therapeutically manipulated if the mechanism of reduced function can be elucidated.
Beta Cell Function After Diagnosis of T1D
The JDRF nPOD (Network for Pancreatic Organ Donors with Diabetes) [29] is a biorepository that collects pancreata from organ donors with T1D, organ donors that are positive for T1D-related autoantibodies, as well as age and sex matched controls. The nPOD project affords access to a unique sample set and allows investigators the ability to perform novel studies and to make observations and test postulates on the pathogenesis of T1D in human specimens that would otherwise be inaccessible. In the nPOD biorepository there are 100 pancreata from individuals diagnosed with T1D. Of this, 34 of the donated pancreata from patients with T1D had insulin positive islets; although in most of these cases the number of islets is significantly reduced. The cases with T1D and insulin positive islets had a later age of onset (15.4±9.6 years vs 11.8±8.3; P=0.003; Mean±SD) and shorter duration of disease (12.0±15.7 years vs 23.8± 18.8; P=0.04; Mean±SD) (Fig. 1) . This suggests that insulin positive β cells are present in approximately 1/3 of the patients with T1D, yet they are dysfunctional.
Further support of impaired beta cell function despite potential residual beta cell mass can be seen from Steele et al's [30] study that demonstrated approximately 30 %-40 % of the patients with established T1D exhibited secretion of insulin in response to a MMTT, yet these individuals remained hyperglycemic. The team also found that the pattern of insulin secretory response within the first 6 months after diagnosis of diabetes is a significant predictor of the rate of loss of insulin secretion. Sherr et al [31] showed significant decline in insulin secretory response to MMTT in human subjects with T1D with early insulin response compared with those with late response. Meal stimulated insulin secretory responses were still seen in those with long standing T1D and detectable c-peptide, which lends further evidence that there may be intrinsic metabolic differences in beta cells in those individuals who retain beta cell function compared with those who do not.
Currently, all data comparing whole body metabolism to histology or function of isolated islet are corollary, as these data do not originate from samples taken from the same individual. Direct data from these categories could only be collected by an effort similar to the DiViD study [32] that would also include metabolic measurements, which is unlikely due to the complications and termination of that protocol [33] . Therefore, a great benefit may come from experimental plans that include cross-talk between human clinical and basic science methodologies with the use of animal models for completion of invasive studies.
NOD Mouse Model
Cross-sectional studies in humans have shown significant metabolic dysfunction during the prediabetes period that worsen during progression of T1D, yet there are limitations for longitudinal and more invasive time course studies. For more involved experiments an animal model could be used, provided that it is a surrogate that reflects the changes observed during pathogenesis of human T1D. The NOD mouse strain has been widely used for research to unravel the genetics of T1D as well as the immunologic mechanisms of T1D. NOD mice have a significant number of genetic and immunologic traits that are shared or have high homology with the human disease [34] . NOD mice have a very aggressive form of autoimmune diabetes. Insulitis develops around 4 weeks of age and leads to beta cell dysfunction and destruction resulting in overt hyperglycemia in~80 % of female and 20 % of male NOD mice by 30 weeks of age.
NOD Characterization of Beta Cell Mass
Although data indicating a progressive decline in insulin response preceding overt hyperglycemia appear to be well received [7, 18-20, 30, 35] , the time course of beta cell failure and destruction remains controversial for human T1D and requires further clarification in the NOD model of T1D. One commonly held view is that there is a gradual and progressive decline in beta cell mass and function that begins shortly before overt onset of disease. Sreenan et al [8] measured beta cell mass and rates of beta cell proliferation as well as insulin secretory responses from the perfused pancreas in NOD and control mice 8-9, 13, and 18 weeks of age and found that beta cell mass was significantly reduced by 42 % in 13-week-old nondiabetic NOD mice, and by 73 % in 18-week-old diabetic NOD mice. In addition, at 18 weeks of age diabetic NOD mice exhibited a reduced insulin secretory response to a greater degree than loss of beta cell mass. After adjusting for confounding factors (ie, whether the reduction in insulin secretion in nondiabetic NOD mice was only due to the reduction in beta cell mass), insulin secretory response to increased glucose and to arginine was still significantly reduced at the 18-week time point, pointing to evidence of beta cell dysfunction in addition to reduced mass. These data give strong quantitative evidence that beta cell mass and function progressively fall before onset of T1D.
Yet an opposing view portends that beta cell mass does not begin to fall until the onset of type 1 diabetes. Shimada et al [36••] found a correlation between cytokine profiles with either their pathogenic or protective roles in NOD mice, and observed a sudden shift in cytokine phenotype from Th2 to Th1 at the onset of hyperglycemia in NOD mice. Preliminary histology of these mice revealed approximately 20-30 insulinpositive islets per slide for the nondiabetic NOD mice compared with only 10 or less insulin-positive islets per slide in those that had developed hyperglycemia. Other studies have shown promising results of durable remission in adult female NOD mice after either anti-thymocyte globulin or anti-CD3 treatment within the first 2-3 days after the onset of overt diabetes [37, 38] . These data suggest that diabetes in the NOD mouse may progress predominantly as inflammatory beta cell dysfunction without actual beta cell destruction until later in the autoimmune disease process. In line with these studies, Sever et al [39] shows that beta cell mass moderately reduced with age, with significant decrease in bioluminescent imaging (BLI) of NOD transgenic mice expressing luciferase gene under control of insulin promoters, indicating a loss of beta cell function, but not necessarily mass, with age and duration of diseases.
Impaired First-Phase Insulin Response to Glucose in NOD
While there has been considerable progress in understanding the natural history of beta cell decline in patients at risk for T1D development, very little is known regarding the changes in beta cell function or mass prior to diabetes onset in the NOD mouse. In the NOD mouse, diabetes is preceded by a preclinical phase in which autoimmune insulitis is associated with persistence of normal fasting blood glucose concentrations. Similar to what has been reported in human beings, a significant decrease in FPIR during an intraperitoneal glucose tolerance test has been observed in NOD mice despite maintenance of glucose tolerance during the prediabetic period [7] . Previously, Reddy and colleague demonstrated a decrease in FPIR in vivo when comparing female NOD mice at 6 weeks and a second cohort at 21 weeks of age [40] . Two additional groups reported reductions in FPIR by pancreas perfusion between 23 and 32, as well as 8 and 18 weeks of age, respectively [7, 8] . These data highlight the fact that as disease progresses, the degree of insulitis appears to be associated with increased fasting glucose and further loss of GSIS, indicating that a defect in FPIR may be an initial indicator of beta cell damage. However, these were all single point measures per mouse and did not demonstrate the progression of ß cell failure serially in individual mice.
We have recently observed, using sequential glucose tolerance tests, that female NOD mice exhibit a steady increase in blood glucose levels that was associated with a progressive decline of FPIR to glucose before onset of diabetes [35] . Additionally, loss of first-phase insulin response to glucose precedes any measurable defect in insulin secretion in response to L-arginine stimulation. These results indicate that the initial sign of beta cell damage in NOD mice is a defect of the first phase of glucose-induced insulin secretion, which is followed by a total loss of the ability to respond to glucose or arginine stimulation. Analogous to findings in human disease progression, the impairment of first phase of glucose-induced insulin secretion could be an early in vivo marker of progressive beta cell failure in NOD mice. As these measurements are similar to those reported in human T1D, studies that elucidate the mechanisms that underlie the loss of glucose responsiveness in NOD islets are likely to generate results that are relevant to the human disease.
NOD Markers of Beta Cell Dysfunction
In addition to using pancreatic islet autoantibodies and genetic screening [41] as means for predicting T1D, we are now finding promising results for new metabolic predictors. Early indicators of T1D progression in humans are consequent from aforementioned studies showing loss of first-phase insulin response to glucose during MMTT's, and findings that preserved C-peptide production in nonprogressors to clinical T1D may help determine response to preventative and diagnostic efforts [6] .
Whether due to intrinsic beta cell dysfunction or exposure to cytokines secreted during the autoimmune attack, these metabolic abnormalities may ultimately a result in mitochondrial damage and dysfunction. Mitochondria are essential for GSIS as these organelles mediate the glucose-induced rise in cellular ATP that closes the K-ATP channels leading to insulin secretion and the downstream maintenance of normal blood glucose levels. Sever et al [39] found that the decreased light emission in Bioluminescence Imaging (BLI) (under the control of insulin promoters) in beta cells from older diabetic NOD mice resulted from the combined effects of reduced beta cell mass, a fall in luciferase mRNA and protein levels, as well as decreased intracellular ATP concentrations. These correlative studies demonstrate the promise for applications of BLI to be used as a noninvasive and more sensitive method for in vivo detection and tracking of early metabolic changes as indicators of early beta cell dysfunction. By further studying differences in mitochondrial protein expression or function in tissues from NOD mice or individuals with and without T1D, we may better predict disease progression and explain why T1D patients fail to secrete insulin despite the persistence of beta cell mass.
Conclusions and Discussion
Individuals with 2 or more AAb, intact FPIR, and normal glucose tolerance have a 30 %-50 % risk of developing diabetes over a 5-year period. When glucose tolerance becomes abnormal, the risk increases to 70 %-90 % over 5 years. Long-term, clinical studies have defined secretagogue responses in patients with long-standing T1D. Patients with long-standing T1D (~40 %) maintain both basal and stimulated c-peptide in an MMTT [24••, 25, 26, 28] albeit reduced compared with levels routinely measured in healthy controls. The similarities in beta cell dysfunction between autoantibody positive individuals and those with established T1D suggest a common mechanism for beta cell failure in most individuals that progress to T1D. However, there remains a need to establish the mechanisms of beta cell dysfunction in these 2 groups.
Future studies should aim at developing new strategies for the in vivo imaging and measuring of pancreatic beta cell mass and function, as clinical and investigational tools for detecting and monitoring the processes leading to clinical phenotypes of T1D. After identifying components of the glucose sensing and insulin secretory machinery pathways that are altered, we could then study high-risk nondiabetic subjects (using MMTT and other insulin secretagogues) to correlate these components with progression and slow or nonprogression to T1D. The NOD mouse model should provide excellent support for these studies due to the similarities in metabolic dysfunction that occur in the mouse and individuals that progress to T1D. NOD mice could be used for longitudinal studies analyst more closely examine disease progression.
Ultimately, understanding metabolic processes in the pathogenesis of disease can better delineate the timeline of beta cell destruction and dysfunction in NOD mice and human models of disease. This additional knowledge should have a major impact on how T1D is treated, as this could provide a means to prevent T1D prior to diagnosis in those identified as highest risk or for reviving residual beta cell function resulting in insulin-free status in a significant number of patients [24••, 25, 26, 28] . The presence of the dysfunctional beta cell mass in these patients (Fig. 1) should provide hope that through therapeutic manipulation, the mechanisms causing impaired function could be reversed and in conjunction with immunotherapy to restore immune tolerance to beta cells disease remission could be attained.
